Ex vivo approaches may include a detailed evaluation of metabolic abnormalities in erythrocytes obtained from cancer patients, with a focus on methemoglobin percentage, ion balance (Na+, K+, Ca2+), and redox profiles compared with healthy controls. The gene discussed is HBG2; the disease is cancer.